Tagged with Biotech,

Pharma Ten years after his first interview with Focus Reports, Wafik Bardissi discusses Minapharm’s position as the leading biosimilar manufacturer in the Middle East. Has Egypt taken steps to incentivize the development or registration of biosimilar products? At present, more attention is required in Egypt to promote biosimilar development or encourage the registration of…

Pharma Pharmaceuticals Giuseppe Martini, President at the National Technological Cluster: Advanced Life Sciences in Italy (ALISEI) discusses the founding of the ALISEI cluster, its main missions and how it helps Italy to promote itself as a research destination on a pan-European level. Mr. Martini, can you give our readers a brief overview…

Pharma Jean-Charles Foddis, executive director of Aderly, Lyon’s main investment agency, discusses the city’s history of economic development while highlighting its main strengths and challenges for the future in life sciences. You came to Aderly in August 2015, having previously worked in a number of different positions predominantly in life sciences.…

Pharma Amatsigroup, a Contract Development and Manufacturing Organization (CDMO), provides services throughout both preclinical and clinical phases. Leading over 200 highly qualified employees with a portfolio of over 300 clients, President Alain Sainsot shares Amatsigroup’s impressive recent growth which positions the company towards being a leading French player in its sector.…

Pharma Nicolas Bardonnet, general manager of Promega France, reveals how France hosts both their European application laboratory and European training centre, offering a wide range of courses in molecular biology, cell biology, proteomics and genetic identity. Mr Bardonnet talks about the importance that Promega attaches to supporting the surrounding community, giving…

Pharma Roeland Van Dam, CEO of Bilthoven Biologicals, a historical Dutch company which remains at the forefront of vaccine production, explains how being integrated into the Serum Institute of India has helped the company to become profitable and consider ambitious new objectives. Bilthoven Biologicals has a very unique history, having started…

Pharma Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system does not capture the benefits that the next generation of gene therapy products deliver over time, transforming chronic diseases into…

Pharma The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising pipeline of innovative products, her “positively opportunistic” attitude towards partnerships and international expansion, and the company’s overall strategy for differentiating…

Pharma The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international partnership strategy and how her diverse background in engineering, medicine and a variety of companies has equipped her to lead…

Pharma Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape of immunotherapy as well as the evolution of the French biotech environment, and finally, their mission to position Effimune as…

Pharma Mr. Michel Finance, CEO of Theradiag, a leading French player in in vitro diagnostics and the novel field of theranostics (a combination of treatment and diagnosis), discusses the major restructuring at Theradiag he oversaw, the crucial role that diagnostics play in the provision of efficient as well as cost-effective healthcare…

pharma Harnessing the power of big data and the Internet, myTomorrows is working to help patients in need to access treatments that would otherwise not be available outside of a clinical trial. CEO Ronald Brus discusses the workings of this unique and disruptive company. As an introduction, given your wealth of experience in…